Detection of human chorionic gonadotrophin-β in serum or urine of prostate cancer patients is of no clinical significance

Tumor Biology

Volumn 27, Issue 4, 2006, Pages 181-186

  Otite, U ^a,b   Baithun, S ^b   Chinegwundoh, F ^b   Nargund, V H ^b   Iles, R K ^a,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c MIDDLESEX UNIVERSITY   (United Kingdom)

Author keywords

Gleason score; Human chorionic gonadotrophin ; Prostate cancer; Prostate specific antigen

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EVALUATION RESEARCH; GLEASON SCORE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE URINE LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; STATISTICAL SIGNIFICANCE;

EID: 33646740160     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093021     Document Type: Article

References (37)

1. Visser O, Coebergh JWW, Schouten LJ, et al: Incidence of Cancer in the Netherlands 1995. 7th Report of the Netherlands Cancer Registry. Utrecht, Vereniging van Integrale Kankercentra, 1998.
2. Landis SH, Murray T, Bolden S, Wing PA: Cancer statistics 1999. CA Cancer J Clin 1999;49:8-31.
3. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Serum PSA after anatomic radical prostatectomy. The John Hopkins experience after 10 years. Urol Clin North Am 1993;20:713.
4. Pound CR, Partin AW, Epstein JL, Walsh PC: Prostate specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
5. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR: Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003;169:157-163.
6. Iles RK, Jenkins BJ, Oliver RTD, Blandy JP, Chard T: Beta human chorionic gonadotrophin in serum and urine. A marker for metastatic urothelial cancer. Br J Urol 1989;64:241-244.
7. Iles RK, Lee CL, Oliver RTD, Chard T: Composition of intact hormone and free β sub-unit in the human chorionic gonadotrophin like material found in the serum and urine of patients with carcinoma of the bladder. Clin Endocrinol 1990;32:355-364.
8. Iles RK, Persad R, Tivedi M, Sharma KB, Dickerson A, Smith P, Chard T: Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker of bladder cancer. Br J Urol 1996;77:61-69.
9. Carter PG, Iles R, Neven P, Ind T, Shepherd J, Chard T: The prognostic significance of urinary β core fragment in pre-menopausal women with carcinoma of the cervix. Gynecol Oncol 1994;55:271-276.
10. Carter PG, Iles RK, Neven P, Ind TEJ, Shepherd J, Chard T: Measurement of urinary beta core fragment of human chorionic gonadotrophin in women with vulvovaginal malignancy and its prognostic significance. Br J Cancer 1995;71:350-353.
11. Sheaff MT, Martin JE, Badenoch DF, Baithun SI: Beta-hCG as a prognostic marker in adenocarcinoma of the prostate. J Clin Pathol 1996;49:329-332.
12. Buchan IE: StatsDirect Ltd, Hertfordshire, UK. www.StatsDirect.com.
13. Braunstein GD, Vaitukaitis JL, Carbone PO, Ross GT: Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Intern Med 1973;78:39-45.
14. Fukutani K, Libby JM, Panko WB, Scardino PT: Human chorionic gonadotrophin detected in urinary concentrates from patients with malignant tumors of the testis, prostate, bladder, ureter and kidney. J Urol 1983;129:74-77.
15. Cole LA, Birken S: Origin and occurrence of human chorionic gonadotrophin beta-subunit core fragment. Mol Endocrinol 1988;2:825-830.
16. Hotakainen K, Ljungberg B, Paju A, Rasmuson T, Alfthan H, Stenman UH: The free beta-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. Br J Cancer 2002;86:185-189.
17. Butler SA, Ikram MS, Mathieu S, Iles RK: The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br J Cancer 2000;82:1553-1536.
18. Iles RK, Javid MK, Gunn LA, Chard T: Cross-reaction with βLH-core can account for all the age dependent rise in βcore/hCGβcf immunoreactivity in women with non-malignant conditions. Clin Chem 1999;45:532-538.
19. McManus LM, Naughton MA, Martinez-Hernandez A: Human chorionic gonadotrophin in human neoplastic cells. Cancer Res 1976;36:3476-3481.
20. Crawford RA, Iles RK, Carter PG, Caldwell CJ, Shepherd JH, Chard T: The prognostic significance of beta human chorionic gonadotrophin and its metabolites in women with cervical carcinoma. J Clin Pathol 1998;51:685-688.
21. Dirnhofer S, Berger C, Hermann M, Steiner G, Madersbacher S, Berger P: Coexpression of gonadotrophic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 1998;35:212-220.
22. Daja MM, Aghmesheh M, Ow KT, Rohde PR, Barrow KD, Russell PJ: Beta-human chorionic gonadotropin in semen: a marker for early detection of prostate cancer? Mol Urol 2000;4:421-427.
23. Span PN, Thomas CMG, Heuvel JJ, Bosch RR, Schalken JA, vd Locht L, Mensink EJBM, Sweep CGJ: Analysis of expression of chorionic gonadotrophin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR. J Endocrinol 2002;172:489-495.
24. Anderson L, Seilhamer J: A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997;18:533-537.
25. Gyri SP, Rochon Y, Franza R, Aebersold R: Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999;19:1720-1730.
26. Davies S: Ectopic Expression of Glycoprotein Hormones and Their Receptors by Urogenital Cancers; PhD thesis, University of London, 2001, p 124.
27. Butler SA, Iles RK: Ectopic hCGB secretion by epithelial tumors and hCGB induced apoptosis in Kaposi's sarcoma - is there a connection? Clin Cancer Res 2003;9:4666-4673.
28. Chodak GW, Thisted RA, Gerber GS, et al: Results of conservative management of clinically localised prostate cancer. N Engl J Med 1994;330:246-248.
29. Albertsen PC, Fryback DG, Storer BE, Kolon TF: Long-term survival among men with conservatively treated localised prostate cancer. JAMA 1995;274:626-631.
30. Feneley MR, Partin AW: Indicators of pathologic stage of prostate cancer and their use in clinical practice. Urol Clin North Am 2001;28:443-458.
31. Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E: External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pre-treatment PSA levels and biopsy Gleason scores. Cancer J Sci Am 1997;3:78-87.
32. May F, Hartung R, Breul J: The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy. BJU Int 2001;88:702-707.
33. Broder LE, Weintraub BD, Rosen SW, Cohen MH, Tejada F: Placental proteins and their subunits as tumour markers in prostatic carcinoma. Cancer 1977;40:211-216.
34. Papapetrou PD, Sakerelou NP, Braouzi H, Fessas PH: Ectopic production of human chorionic gonadotrophin (HCG) by neoplasms: the value of measurements of immunoreactive HCG in urine as a screening procedure. Cancer 1980;45:2583-2592.
35. Menon M, Stefani SS: Evaluation of human chorionic gonadotrophin-β levels in prostatic carcinoma. Urol Int 1980;35:291-293.
36. Purnell DM, Heatfield BM, Trump BF: Immunocytochemical evaluation of human prostatic carcinoma for carcinoembryonic antigen, non-specific cross-reacting antigen, β-chorionic gonadotrophin, and prostate-specific antigen. Cancer Res 1984;44:285-292.
37. Shah VM, Newman J, Crocker J, Antonakopoulos GN, Chapple CR, Collard MJ: Production of β-human chorionic gonadotrophin by prostatic adenocarcinoma and transitional cell carcinoma of the upper urinary tract. Br J Exp Pathol 1987;68:871-878.